Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MM-151 + trametinib
- Development stage
- Discontinued
- Lead developer
- Merrimack Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
MM-151 + trametinib is a combination investigational therapy of MM-151, an anti-EGFR monoclonal antibody, and trametinib, a selective MEK1/2 inhibitor. MM-151 targets and blocks multiple epitopes of the epidermal growth factor receptor (EGFR), inhibiting ligand-induced activation and downstream cancer-promoting signaling. Trametinib inhibits MEK1 and MEK2 enzymes in the MAPK/ERK pathway, preventing cancer cell proliferation driven by RAS-RAF-MEK-ERK signaling. This combination aims to overcome resistance mechanisms in tumors, particularly those reliant on EGFR and MAPK pathway activation, including certain colorectal cancers and other advanced solid tumors.
- Other names
- trametinibMM-151MM151MM 151
02
Targets
EGFR (Epidermal growth factor receptor)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on MM-151 + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MM-151 + trametinib.